The report provides a detailed disclosure about FSG Fund II, focusing on its alignment with environmental and social characteristics under Article 8 of the Sustainable Finance Disclosure Regulation (SFDR).

‍

Key Contents

‍

Purpose and Objectives:

• The fund aims to promote environmental and social benefits by investing in companies addressing unmet medical needs and supporting the United Nations Sustainable Development Goals (SDGs), including Good Health & Well-Being (SDG 3), Gender Equality (SDG 5), and Climate Action (SDG 13).

‍

Investment Strategy:

• Focus on life sciences and technology sectors.

• Excludes investments in industries like fossil fuels, tobacco, weapons, and other sectors with significant sustainability challenges.

‍

Performance Indicators:

• OssDsign and Saga Dx are the primary portfolio companies, with metrics tracked for gender representation, governance quality, and carbon footprint reduction initiatives.

• Both companies demonstrated compliance with ESG goals, with no reported ESG incidents.

‍

Sustainability Achievements:

• 100% of investments aligned with the fund’s environmental and social objectives.

• Implementation of tailored ESG Action Plans for portfolio companies to improve sustainability governance and practices.

‍

Limitations and Alignment:

• No investments classified as sustainable under the EU Taxonomy.

• Report does not include historical comparisons, as this is the first disclosure (covering 2023).

‍

Governance and Support:

• Active engagement with portfolio companies’ leadership teams to drive sustainability initiatives, supported by periodic reviews and risk-based approaches.